Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
NCT04314089
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Non-small Cell Lung Cancer
Interventions
DRUG:
GT103
Sponsor
Edward Patz